neurostimulation
The Massachusetts-based company will use the funds to advance its Spectris neurotechnology platform that uses visual and auditory stimulation to treat Alzheimer's disease.
The digital platform enables clinicians to adjust their patient's devices remotely and in real-time.
The nearly 14-year-old company hopes to raise $75 million to support its implanted, closed-loop seizure prevention system.
The company's implanted product acts as a closed-loop system that monitors and responds to brain activity by automatically delivering stimulation prior to the start of a seizure.
The system may now be used to target patients' internal globus pallidus, a portion of the brain associated with Parkinson's disease symptoms.